Crinetics Pharmaceuticals (CRNX) Liabilities and Shareholders Equity (2017 - 2026)

Crinetics Pharmaceuticals has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $1.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 2.94% year-over-year to $1.4 billion; the trailing twelve-month figure through Mar 2026 stood at $5.0 billion (up 7.38% YoY), and the FY2025 full-year result was $1.1 billion, down 21.49% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.4 billion, up from $1.1 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.4 billion in Q4 2024, with the low at $293.3 million in Q2 2023.
• Average Liabilities and Shareholders Equity over 5 years is $825.7 million, with a median of $935.5 million recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity plunged 30.46% in 2023 and soared 219.02% in 2024.
• Tracing CRNX's Liabilities and Shareholders Equity over 5 years: stood at $352.2 million in 2022, then surged by 80.41% to $635.4 million in 2023, then surged by 125.79% to $1.4 billion in 2024, then retreated by 21.49% to $1.1 billion in 2025, then grew by 24.42% to $1.4 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.4 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.

Peer Comparison